MedPath

Triple-blind clinical trial on the effect of a combination of garlic, silymarin and curcumin in comparison with placebo in the treatment of non-alcoholic fatty liver disease

Phase 2
Recruiting
Conditions
fatty liver disease.
Fatty (change of) liver, not elsewhere classified
K76.0
Registration Number
IRCT20190602043787N1
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

increased LFT plus sonographic evidenses of NAFLD
age between 18-70 years

Exclusion Criteria

diabetes mellitus
hypothyioidism
any drug users
sever cardiac disease or sever polmunary disease or past medical history of liver disease,cirrhosis,cancer
pregnancy and lactation
abnormal test include:ANA,HCV Ab,HBC Ab,HBS Ag,Anti TTG IgA,TIBC,Ferritin,SI,ASMA,seroloplasmin

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.decrease in serum level of ALT. Timepoint: at the baseline and 3 months after intervention. Method of measurement: autoanalyzer bt3000.
Secondary Outcome Measures
NameTimeMethod
Decrease in ultrasonographic grading. Timepoint: at the baseline and 3 months after intervention. Method of measurement: ultrasonography.
© Copyright 2025. All Rights Reserved by MedPath